KEYNOTE-671, KEYTRUDA, Merck, NSCLC, Pembrolizumab
Neoadjuvant/ adjuvant pembrolizumab is approved by the FDA for resectable non-small cell lung cancer
Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
Pembrolizumab, USFDA
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Feb 2024: The Food and Drug Administration has sped up the approval process for two drugs, enfortumab vedotin-ejfv (Padcev, Astellas Pharma) and pembrolizumab (Keytruda, Merck). These drugs are meant to treat people with locally ..
FDA, Food and Drug Administration, KEYTRUDA, Merck, Pembrolizumab, platinum-based chemotherapy
Pembrolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer
Feb 2023: For stage IB (T2a 4 cm), stage II, or stage IIIA non-small cell lung cancer, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) as adjuvant therapy after resection and platinum-based chemoth..
KEYTRUDA, Merck, Pembrolizumab, Roche Tissue Diagnostics, Ventana Medical Systems
Pembrolizumab is approved for advanced endometrial carcinoma
April 2022: Pembrolizumab (Keytruda, Merck) was approved by the Food and Drug Administration as a single agent for patients with advanced endometrial carcinoma that is microsatellite instability-high (MSI-H) or mismatch repair de..
NCT03142334, Pembrolizumab, renal cell carcinoma
Pembrolizumab is approved for adjuvant treatment of renal cell carcinoma
Jan 2022: Pembrolizumab (Keytruda, Merck) has been approved by the Food and Drug Administration for the adjuvant treatment of patients with renal cell carcinoma (RCC) who are at intermediate-high or high risk of recurrence after ..
Bevacizumab, KEYTRUDA, Merck, PD-L1, Pembrolizumab
Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer
Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration for patients with persistent, recurrent, or metastatic cervical cancer ..
KEYTRUDA, Merck, Pembrolizumab, TNBC
Pembrolizumab has been approved by the FDA for high-risk early-stage triple-negative breast cancer
August 2021: Pembrolizumab (Keytruda, Merck) was approved by the FDA for high-risk, early-stage triple-negative breast cancer (TNBC) as a neoadjuvant treatment in combination with chemotherapy, and later as a single agent as adjuv..
Eisai, KEYTRUDA, Lenvatinib, Lenvima, Merck, NCT03517449, Pembrolizumab
Pembrolizumab and lenvatinib have been approved by the FDA for advanced endometrial cancer
August 2021: Pembrolizumab (Keytruda, Merck) in combination with lenvatinib (Lenvima, Eisai) has been approved by the Food and Drug Administration for patients with advanced endometrial carcinoma that is not microsatellite instabi..
fluoropyrimidine, gastroesophageal junction (GEJ) adenocarcinoma, KEYTRUDA, Merck & Co, Pembrolizumab, Trastuzumab
Pembrolizumab receives accelerated approval from the FDA for HER2-positive gastric cancer
August 2021: Pembrolizumab (Keytruda, Merck & Co.) in combination with trastuzumab, fluoropyrimidine-, and platinum-containing chemotherapy has been granted accelerated approval by the Food and Drug Administration for the firs..
cisplatin, esophageal carcinoma, fluorouracil, GEJ, KEYNOTE-590, NCT03189719, Pembrolizumab
Pembrolizumab has been approved by the FDA for the treatment of esophageal or gastroesophageal junction cancer
August 2021: Pembrolizumab (Keytruda, Merck Sharp & Dohme Corp.) in combination with platinum and fluoropyrimidine-based chemotherapy has been approved by the Food and Drug Administration for patients with metastatic or locall..